Journal
CURRENT HYPERTENSION REPORTS
Volume 13, Issue 4, Pages 269-275Publisher
SPRINGER
DOI: 10.1007/s11906-011-0204-0
Keywords
Preeclampsia; Placental ischemia; Placental hypoxia; VEGF; sFlt-1; Heme oxygenase-1; Endothelin-1; Sildenafil; Hypertension; Pregnancy; Treatment
Categories
Funding
- NHLBI NIH HHS [R01 HL108618] Funding Source: Medline
Ask authors/readers for more resources
Preeclampsia is a pregnancy-induced hypertensive disorder found most commonly in nulliparous women. Recent research performed in animal models of the disease has revealed some of the underlying mechanisms of preeclampsia. Specifically, placental insufficiency and the resulting hypoxia/ischemia have been shown to be crucial to disease progression. In response to placental hypoxia/ischemia, several pathways are activated, which contribute to the clinical manifestations of the disease: increased circulating levels of the anti-angiogenic protein sFlt-1, activation of the maternal inflammatory response, suppressed nitric oxide production, enhanced endothelin-1 production, and induction of reactive oxygen formation. Despite advances in the understanding of the disorder, therapeutic approaches to the treatment of preeclampsia are severely limited. New lines of research, however, indicate some possible new therapeutic approaches for the management of preeclampsia and offer hope for an effective pharmacologic intervention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available